Pioglitazone and Bladder Cancer
Open Access
- 16 January 2012
- journal article
- Published by American Diabetes Association in Diabetes Care
- Vol. 35 (2), 278-280
- https://doi.org/10.2337/dc11-1449
Abstract
OBJECTIVE: The association between pioglitazone and bladder cancer has not been investigated in Asians. We aimed to investigate this association. RESEARCH DESIGN AND METHODS: A total of 1,000,000 individuals were randomly sampled from the National Health Insurance database, and incident cases of bladder cancer during the period from 1 January 2006 to 31 December 2009 were analyzed among 54,928 patients with type 2 diabetes and without previous bladder cancer. RESULTS: Among 165 incident case subjects, 10 (0.39%) were ever users and 155 (0.30%) were never users of pioglitazone (adjusted hazard ratio in full model 1.305 [95% CI 0.661–2.576]). All bladder cancer in ever users occurred within a duration of therapy <24 months, suggesting an early effect of pioglitazone on bladder cancer or late use of pioglitazone in high-risk patients. CONCLUSIONS: The association between pioglitazone and bladder cancer was not significant. However, confirmation of this finding is required because of the possible lack of statistical power owing to the small number of events.Keywords
This publication has 14 references indexed in Scilit:
- Diabetes and non-Hodgkin’s lymphoma: analyses of prevalence and annual incidence in 2005 using the National Health Insurance database in TaiwanAnnals Of Oncology, 2011
- Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event ReportingDiabetes Care, 2011
- Risk of Bladder Cancer Among Diabetic Patients Treated With PioglitazoneDiabetes Care, 2011
- Diabetes and Risk of Prostate CancerDiabetes Care, 2011
- The influence of glucose-lowering therapies on cancer risk in type 2 diabetesDiabetologia, 2009
- Age-related risk of mortality from bladder cancer in diabetic patients: A 12-year follow-up of a national cohort in TaiwanAnnals of Medicine, 2009
- Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 DiabetesDrug Safety, 2009
- Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular CausesNew England Journal of Medicine, 2007
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialThe Lancet, 2005
- SIMPLE METHOD TO CALCULATE THE CONFIDENCE INTERVAL OF A STANDARDIZED MORTALITY RATIO (SMR)American Journal of Epidemiology, 1990